دورية أكاديمية
أعرض في EDS

HCC-Check: A Novel Diagnostic Tool for Early Detection of Hepatocellular Carcinoma Based on Cytokeratin-1 and Epithelial Membrane Antigen: A Cross-Sectional Study.

التفاصيل البيبلوغرافية
العنوان: HCC-Check: A Novel Diagnostic Tool for Early Detection of Hepatocellular Carcinoma Based on Cytokeratin-1 and Epithelial Membrane Antigen: A Cross-Sectional Study.
المؤلفون: Attallah KA; Research and Development Department, Biotechnology Research Center, New Damietta, Egypt.; Clinical Research Department, Damietta Directorate for Health Affairs, Egyptian Ministry of Health and Population, Damietta, Egypt., Albannan MS; Research and Development Department, Biotechnology Research Center, New Damietta, Egypt., Farid K; Faculty of Medicine, Mansoura University, Mansoura, Egypt., Rizk SM; Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Fathy N; Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
المصدر: Technology in cancer research & treatment [Technol Cancer Res Treat] 2024 Jan-Dec; Vol. 23, pp. 15330338241234790.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: SAGE Country of Publication: United States NLM ID: 101140941 Publication Model: Print Cited Medium: Internet ISSN: 1533-0338 (Electronic) Linking ISSN: 15330338 NLM ISO Abbreviation: Technol Cancer Res Treat Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015-: Thousand Oaks, CA : SAGE
Original Publication: Schenectady, NY : Adenine Press, c2002-
مواضيع طبية MeSH: Carcinoma, Hepatocellular*/diagnosis , Liver Neoplasms*/diagnosis, Humans ; Cross-Sectional Studies ; Early Diagnosis ; Mucin-1 ; Reproducibility of Results ; Keratin-1
مستخلص: Background: Hepatocellular carcinoma is frequently diagnosed in advanced stages, leading to a poorer prognosis. Therefore, early diagnosis and identification of biomarkers may significantly improve outcomes. Methods: This cross-sectional study enrolled 486 participants distributed among 3 groups: F1 to F3 = 184, F4 = 183, and hepatocellular carcinoma = 119. Liver fibrosis staging was performed using FibroScan, while imaging features were used for hepatocellular carcinoma detection. Epithelial membrane antigen and cytokeratin-1 levels in serum were quantified through Western blot and ELISA, respectively. Results: Patients diagnosed with hepatocellular carcinoma exhibited significantly elevated levels of epithelial membrane antigen and cytokeratin-1 compared to non-hepatocellular carcinoma patients, with a highly significant statistical difference ( P  < .0001). Epithelial membrane antigen demonstrated diagnostic performance with an area under the curve of 0.75, a sensitivity of 69.0%, and a specificity of 68.5%. Cytokeratin-1 for the identification of hepatocellular carcinoma showed a sensitivity of 79.0% and a specificity of 81.4%, resulting in an area under the curve of 0.87. The developed HCC-Check, which incorporates epithelial membrane antigen, cytokeratin-1, albumin, and alpha-fetoprotein, displayed a higher area under the curve of 0.95 to identify hepatocellular carcinoma, with a sensitivity of 89.8% and a specificity of 83.9%. Notably, HCC-Check values exceeding 2.57 substantially increased the likelihood of hepatocellular carcinoma, with an estimated odds ratio of 50.65, indicating a higher susceptibility to hepatocellular carcinoma development than those with lower values. The HCC-Check diagnostic test exhibited high precision in identifying patients with hepatocellular carcinoma, particularly those with small tumor sizes (<5 cm) and a single nodule, as reflected in area under the curve values of 0.92 and 0.85, respectively. HCC-Check was then applied to the validation study to test its accuracy and reproducibility, showing superior area under the curves for identifying different stages of hepatocellular carcinoma. These outcomes underscore the effectiveness of the test in the early detection of hepatocellular carcinoma. Conclusion: The HCC-Check test presents a highly accurate diagnostic method for detecting hepatocellular carcinoma in its early stages.
Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
References: Aliment Pharmacol Ther. 2009 Dec 1;30(11-12):1103-9. (PMID: 19769633)
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):531-538. (PMID: 30464023)
Clin Chim Acta. 2011 Nov 20;412(23-24):2310-5. (PMID: 21924253)
Can J Gastroenterol Hepatol. 2015 May;29(4):178-84. (PMID: 25965437)
Ann Hepatol. 2019 Jan - Feb;18(1):58-67. (PMID: 31113610)
BMC Cancer. 2021 Apr 13;21(1):401. (PMID: 33849479)
PLoS One. 2014 Aug 15;9(8):e105094. (PMID: 25126747)
Int J Biol Sci. 2022 Jan 1;18(2):536-551. (PMID: 35002508)
Dig Dis Sci. 2019 Apr;64(4):910-917. (PMID: 30835028)
World J Gastrointest Oncol. 2021 Apr 15;13(4):197-215. (PMID: 33889272)
Ultrasound Med Biol. 2003 Dec;29(12):1705-13. (PMID: 14698338)
Nature. 1970 Aug 15;227(5259):680-5. (PMID: 5432063)
J Hepatol. 2020 Feb;72(2):250-261. (PMID: 31954490)
World J Gastroenterol. 2009 Sep 21;15(35):4387-91. (PMID: 19764089)
Oncol Rep. 2006 Sep;16(3):473-7. (PMID: 16865245)
Clin Biochem. 2004 Jul;37(7):529-40. (PMID: 15234234)
Ann Intern Med. 2007 Oct 16;147(8):573-7. (PMID: 17938396)
Tumour Biol. 2007;28(4):189-95. (PMID: 17717426)
Quant Imaging Med Surg. 2020 Mar;10(3):805-807. (PMID: 32269940)
Br J Cancer. 2003 Jun 16;88(12):1878-82. (PMID: 12799630)
Transl Oncol. 2022 Jun;20:101422. (PMID: 35430532)
Hepatology. 2023 Jul 1;78(1):319-362. (PMID: 36082510)
Ann Hepatol. 2015 Nov-Dec;14(6):869-80. (PMID: 26436359)
Trends Mol Med. 2014 Jun;20(6):332-42. (PMID: 24667139)
Transpl Int. 2020 May;33(5):567-575. (PMID: 31994238)
Eur J Cancer. 2012 Mar;48(5):599-641. (PMID: 22424278)
Arab J Gastroenterol. 2020 Jun;21(2):102-105. (PMID: 32439235)
Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4. (PMID: 388439)
Hepatology. 2005 Nov;42(5):1208-36. (PMID: 16250051)
Arch Pathol Lab Med. 2017 Aug;141(8):1072-1091. (PMID: 28745570)
Hum Pathol. 1996 Jun;27(6):599-604. (PMID: 8666372)
Curr Gene Ther. 2020;20(2):84-99. (PMID: 32600231)
J Hepatol. 2001 Apr;34(4):570-5. (PMID: 11394657)
فهرسة مساهمة: Keywords: HCC-Check; cytokeratin-1; diagnosis; epithelial membrane antigen; liver
المشرفين على المادة: 0 (Mucin-1)
0 (KRT1 protein, human)
0 (Keratin-1)
تواريخ الأحداث: Date Created: 20240304 Date Completed: 20240305 Latest Revision: 20240325
رمز التحديث: 20240326
مُعرف محوري في PubMed: PMC10913511
DOI: 10.1177/15330338241234790
PMID: 38436112
قاعدة البيانات: MEDLINE
الوصف
تدمد:1533-0338
DOI:10.1177/15330338241234790